Lundbeck Q3 2019 Financial Results
Abide - adding new drug discovery platform with potential to deliver
first-in-class compounds across multiple CNS indications
The transaction:
* Upfront payment: USD 250
ABIDETHERAPEUTICS
million
*
Financed through existing
Now Lundbeck La Jolla Research
Center
financial reserves
*
*
Acquisition reached final
Focused on Serine Hydrolase (S-H)
biology
approval on 29 May 2019
*
to discover first in class S-H
Future milestones: Up to USD
inhibitors
150 million in R&D¹) and sales
milestones²)
Unique chemo-proteomic platform
Headquarters: La Jolla, CA
*
*
*
Strong ties to The Scripps Research
Institute (TSRI) and Dr. Cravatt
Labs.
*
1)
Triggered when stat-sig. results in a phase II clinical trial in the
Tourette's indication or first patient enrolled in a phase III trial in
Tourette's using the lead compound.
2)
First commercial launch and when revenue reach certain thresholds
25 Employees
Serine hydrolase (S-H)
Enzyme Superfamily
One of the largest and most
diverse enzyme classes in humans
Profoundly influence multiple
biological processes in health and
disease
Mood, pain, perception,
movement, inflammation
Selective inhibitors can restore
physiological balance in
dysregulated signalling pathways
Multiple blockbuster drug classes
from this family
*
DPP-4 inhibitors; AChE inhibitors;
Thrombin inhibitors; Xa inhibitors
28
LundbeckView entire presentation